Our novel sepsis treatment, called SUR-101, which we develop collaboratively by the Centre for Cellular and Molecular Platforms (C-CAMP) and the Institute of Life Sciences in India, was official licensed to Dutch biotech firm SurvivX in the presence of Netherlands Prime Minister Mark Rutte .
The development of SUR-101, was presented at an event with Rutte on the latter’s visit to Bengaluru on the sidelines of a G20 summit in India.
The meeting with PM Rutte made headlines in the newspapers in India.
The collaboration between Netherlands and India was heralded as a true global partnership for a global health issue! “This cutting-edge immunomodulatory therapy could be a game-changer in the battle against sepsis, a global threat claiming 20% of lives!”
The collaboration exemplifies the power of global partnerships to address global healthcare challenges!
For more, see for example the coverage in the Indian Express